Treatment of antibody-drug conjugates in elderly patients
10.16352/j.issn.1001-6325.2025.10.1270
- VernacularTitle:抗体药物偶联物在老年肿瘤患者中的治疗
- Author:
Fengshuo LIU
1
;
Mei GUAN
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院 肿瘤内科,北京 100730
- Keywords:
antibody-drug conjugates;
elder patients;
cancer treatment;
targeted therapy
- From:
Basic & Clinical Medicine
2025;45(10):1270-1276
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugates(ADCs)are emerging anti-cancer drugs that have been widely applied in the treatment of hematological and solid tumors.ADCs deliver cytotoxic drugs to tumor cells with precision through anti-body targeting,enhancing efficacy while reducing side effects.Elderly cancer patients face treatment challenges due to factors such as drug metabolism,multiple comorbidities and decreased physical function.However,ADCs have therapeutic advantages in elderly patients.The article discusses the efficacy,safety,dosing strategies,and adverse reaction management of ADCs in elderly patients,in order to provide effective and safe treatment options for elderly cancer patients.
